Consensus Alpha Tau Medical Ltd.

Equities

Market Closed - Nasdaq Other stock markets 21:30:00 15/05/2024 BST			5-day change	1st Jan Change
2.65 ^USD	+0.61%		+9.96%	-11.96%

05-06	Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow	CI
03-07	Alpha Tau Medical Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

bbfccc8243968.bPytPEF7MEOIBtkNWAPKANxBSM5zQLGTLh34yLDc7YY.NY_PaTs1eQ3hcaA-CjLnaogYDp0QB-nkHliRj4OIuM8Gn55kCxJpBOJ37Q~385b15aff4541c6d625edfc541a75ab4

Piper Sandler Adjusts Alpha Tau Medical's Price Target to $8 From $12, Keeps Overweight Rating	11-17	MT
HC Wainwright Starts Alpha Tau Medical at Buy With $9 Price Target	24/04/23	MT
Piper Sandler Adjusts Alpha Tau Medical's Price Target to $12 From $19, Keeps Overweight Rating	23/11/22	MT
Cantor Fitzgerald Initiates Alpha Tau Medical at Overweight with $20 Price Target	14/04/22	MT
Piper Sandler Starts Alpha Tau Medical at Overweight With $19 Price Target	08/04/22	MT
Citigroup Initiates Alpha Tau Medical at Buy With $21 Price Target	04/04/22	MT

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.65 USD

Average target price

9.25 USD

Spread / Average Target

+249.06%

High Price Target

13 USD

Spread / Highest target

+390.57%

Low Price Target

7 USD

Spread / Lowest Target

+164.15%